Fig. 1.

NLRP3 agonist improves radiation-induced primary tumor control. a Establishment of 344SQ-P and 344SQ-R models and treatment strategy. On day 0, primary tumors were subcutaneously injected into the right legs of 129Sv/Ev mice (n = 5 mice/group). Three days later, secondary tumors were injected into the left legs. Anti-PD1 was intraperitoneally (i.p.) started on day 5. XRT to the primary tumors started on day 6. NLRP3 agonist was intratumorally injected (i.t.) to the primary tumor starting on day 9 for 3 doses. Survival curves of 12Gy in 344SQ-P (b) and 344SQ-R models (c). Tumor growth curves of primary tumors of 12Gy in 344SQ-P (d) and 344SQ-R models (e). Survival was plotted by the Kaplan–Meier method. Two-way analysis of variance with multiple comparisons was used to analyze the tumor growth curves. **P < 0.01; ****P < 0.0001; ns, not significant